Ethanol is one of the most widely used excipients in pharmaceuticals, functioning as a solvent, preservative and processing aid. Because of its broad applications and direct impact on patient safety, regulators require that ethanol used in medicines meets the same quality, safety and compliance standards as active pharmaceutical ingredients (APIs).
Pharmacopoeial Standards (USP, Ph. Eur., JP)
Ethanol used in pharmaceuticals must conform to monographs in leading pharmacopoeias:
- United States Pharmacopoeia (USP) – “Alcohol” monograph, specifying identity, assay, limits for methanol and other impurities
- European Pharmacopoeia (Ph. Eur.) – “Ethanol (96 per cent)” and “Ethanol Anhydrous” monographs
- Japanese Pharmacopoeia (JP) – equivalent specifications for ethanol grades
These monographs ensure ethanol consistency across markets, and manufacturers must demonstrate compliance batch by batch via Certificates of Analysis (CoAs).
ICH Q7 – The Foundation of GMP for Excipients
The International Council for Harmonisation (ICH) Q7 guideline sets out Good Manufacturing Practice (GMP) requirements for active substances. For excipients considered at high risk, the same principles are applied. For ethanol, this means:
- Documented, validated processes covering production, packaging, and distribution
- Robust quality systems, including deviation management and corrective actions
- Traceability of feedstocks and intermediates used in ethanol production
USP <1078> – GMP for Bulk Pharmaceutical Excipients
The USP General Chapter <1078> provides guidelines for the application of GMP principles to excipients, recommending:
- Controlled manufacturing and packaging environments
- Prevention of contamination and mix-ups
- Supplier qualification and auditing as part of a risk-based quality system
This framework reinforces that excipients, including ethanol, cannot be treated as commodities.
EXCiPACT and Industry Certification Schemes
Beyond traditional GMP, industry-led schemes such as EXCiPACT GMP and NSF/IPEC/ANSI 363-2024 provide certification specific to excipients. These schemes:
- Offer independent, third-party audits of excipient producers
- Reduce audit burden for pharmaceutical companies
- Are increasingly accepted by regulators as evidence of GMP compliance
For ethanol producers, EXCiPACT GMP certification is now widely regarded as a baseline requirement to access regulated markets.
EMA and FDA Expectations
Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) require that marketing authorisation holders implement risk-based supplier qualification for excipients. For ethanol, this means:
- Verifying GMP or EXCiPACT certification
- Auditing suppliers where risk is deemed high
- Maintaining documented evidence of supplier controls in quality management systems
Failure to do so has already resulted in Form FDA 483 observations and similar regulatory inspection findings for manufacturers.
Regulators worldwide view excipients as integral to the safety and quality of medicines. Ethanol, because of its multifunctional role and widespread use, is subject to rigorous expectations: GMP compliance, pharmacopoeial conformity and documented supplier qualification.
For manufacturers, sourcing ethanol without GMP certification is not only a compliance risk — it is increasingly unacceptable to regulators. Meeting these expectations is essential for safeguarding patients, protecting supply chains, and sustaining market access.
Partner with Kimia for EXCiPACT GMP-certified ethanol, ensuring your formulations meet global regulatory expectations with confidence.
